Aneil Batra

Former VP, Obesity & IM Commercial Strategy & Innovation Pfizer

Aneil Batra is a transformational purpose-driven global healthcare executive with 30 years of experience building and scaling businesses, driving sustainable blockbuster growth, transforming pipelines, and building diverse team cultures of accountability and high performance. He has managed and propelled multibillion dollar blockbuster brands and is a trusted advisor to C-Suite leaders and Board of Directors.

At Pfizer Inc., Aneil reported to the Chief Business and Innovation Officer as the Obesity and IM Commercial Strategy & Innovation Lead. He led the development of the obesity and internal medicine category strategy leading to the acquisition of Metsera ($10B) and an oral GLP-1 from YaoPharma ($150M upfront). He set the clinical and commercial strategy for MET097 and MET097/MET233 fixed-dose combination.

At Novo Nordisk Inc., Aneil was a member of the Novo Nordisk US Management Board and the Global Obesity Management Board, serving as the top senior US executive accountable for the obesity business. During his tenure as Vice President, US Head of Obesity, Aneil built and scaled the obesity business from a ~$70M single-product startup to a ~$5B high-growth multi-product business, achieving 69% YOY volume increase and 50% YOY sales boost.

Aneil has built a reputation for operational excellence that delivers sustainable blockbuster growth. Known for his ability to identify opportunities by leveraging data analytics, his strategic oversight and full P&L ownership drove ROI to maximize the value of marketing investments from 2:1 to 8.6:1 while improving operating margin from ~5% to ~70%. He led the launch of Wegovy® within 72 hours of FDA approval, making it the most successful launch in company history, driving its sales from $220M to $4.3B in just two years. While doing so, he championed the use cognitive neuroscience and behavioral change psychology to revolutionize the marketing strategy and pioneered the use of AI and advanced predictive models.

Leveraging scientific aptitude, Aneil championed early lifecycle decisions to pursue a cardiovascular outcomes trial that led to a ~$50B market cap increase and an unprecedented opening session of the 2023 AHA Scientific Sessions – propelling Novo Nordisk A/S to become the most valuable company in Europe. Prior to this, Aneil provided strategic commercial development leadership for Orilissa™ / Oriahnn™, a ~$1.9B late-stage compound in women's health for AbbVie. While at Takeda Pharmaceuticals, he led the strategic expansion and optimization of Takeda's product portfolio, establishing a new core therapeutic focus in immunology / gastroenterology with Entyvio® ($6.5B blockbuster) and neuroscience with the blockbuster TrintellixTM, earning him two method of use patents. He played a key role in identifying and evaluating 80 global business development opportunities, successfully in-licensing TrintellixTM for $400M, and leading the assessments for 14 M&A candidates, culminating in the $14B acquisition of Nycomed.

Aneil is a people-focused leader who builds high-performance cultures rooted in transparency, diversity, and accountability. He has consistently developed and led teams to exceed business goals with a focus on patients, as exemplified by the expansion of over 1.2M new treated patients at Novo Nordisk.

Recognized by MM+M as a Healthcare Marketing Influencer 25 Class of 2024 and PM360 as a Transformational Leader (2024, 2019), Aneil's leadership has been recognized with numerous awards from Novo Nordisk, Takeda Pharmaceuticals, Eli Lilly, and Parke-Davis. He earned his MBA in Strategic Management, Finance, and Marketing from The University of Chicago Booth School of Business and earned a bachelor's degree in Zoology from Miami University (Oxford, OH)